Adriana Guadalupe Quiroz Reyes

Dr. Adriana Guadalupe Quiroz Reyes

Biochemistry and Molecular biology, Facultad de Medicina, Universidad Autónoma de Nuevo León., Monterrey, Nuevo León, Mexico
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
CGCarlos A. Gonzalez-Villarreal
Carlos A. Gonzalez-Villarreal
ARAdriana Guadalupe Quiroz Reyes
Adriana Guadalupe Quiroz Reyes
JIJose Francisco Islas
Jose Francisco Islas
EGElsa Garza-Treviño
Elsa Garza-Treviño
Colorectal carcinoma (CRC) is a leading cause of cancer mortality. Tumorigenesis is a dynamic process wherein cancer stem cells (CSCs) and their microenvironment promote initiation, progression, and metastasis. Metastatic colonization is an inefficient process that is very complex and is poorly understood; however, in most cases, metastatic disease is not curable, and resistance mechanisms tend to develop against conventional treatments. An understanding of the underlying mechanisms and factors that contribute to the development of metastasis in CRC can aid in the search for specific therapeutic targets for improving standard treatments. In this review, we summarize current knowledge regarding tumor biology and the use of stroma cells as prognostic factors and inflammatory inducers associated with the use of tumor microenvironments as a promoter of cancer metastasis. Moreover, we look into the importance of CSC, pericytes, and circulating tumor cells as mechanisms that lead to liver metastasis, and we also focus on the cellular and molecular pathways that modulate and regulate epithelial–mesenchymal transition. Finally, we discuss a novel therapeutic target that can potentially eliminate CSCs as a CRC treatment.

10 July 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ARAdriana Guadalupe Quiroz Reyes
Adriana Guadalupe Quiroz Reyes
PDPaulina Delgado-Gonzalez
Paulina Delgado-Gonzalez
JIJose Francisco Islas
Jose Francisco Islas
JDJuan Luis Delgado
Juan Luis Delgado
JGJavier Humberto Martínez Garza
Javier Humberto Martínez Garza
EGElsa Garza-Treviño
Elsa Garza-Treviño
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also known as Apo-2 ligand (Apo2L), is a member of the TNF cytokine superfamily. TRAIL has been widely studied as a novel strategy for tumor elimination, as cancer cells overexpress TRAIL death receptors, inducing apoptosis and inhibiting blood vessel formation. However, cancer stem cells (CSCs), which are the main culprits responsible for therapy resistance and cancer remission, can easily develop evasion mechanisms for TRAIL apoptosis. By further modifying their properties, they take advantage of this molecule to improve survival and angiogenesis. The molecular mechanisms that CSCs use for TRAIL resistance and angiogenesis development are not well elucidated. Recent research has shown that proteins and transcription factors from the cell cycle, survival, and invasion pathways are involved. This review summarizes the main mechanism of cell adaption by TRAIL to promote response angiogenic or pro-angiogenic intermediates that facilitate TRAIL resistance regulation and cancer progression by CSCs and novel strategies to induce apoptosis.

14 January 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ARAdriana Guadalupe Quiroz Reyes
Adriana Guadalupe Quiroz Reyes
JIJose Francisco Islas
Jose Francisco Islas
PDPaulina Delgado-Gonzalez
Paulina Delgado-Gonzalez
HFHector Franco-Villarreal
Hector Franco-Villarreal
EGElsa Garza-Treviño
Elsa Garza-Treviño
Metastasis is the process of dissemination of a tumor, whereby cells from the primary site dislodge and find their way to other tissues where secondary tumors establish. Metastasis is the primary cause of death related to cancer. This process warrants changes in original tumoral cells and their microenvironment to establish a metastatic niche. Traditionally, cancer therapy has focused on metastasis prevention by systematic treatments or direct surgical re-sectioning. However, metastasis can still occur. More recently, new therapies direct their attention to targeting cancer stem cells. As they propose, these cells could be the orchestrators of the metastatic niche. In this review, we describe conventional and novel developments in cancer therapeutics for liver and lung metastasis. We further discuss the resistance mechanisms of targeted therapy, the advantages, and disadvantages of diverse treatment approaches, and future novel strategies to enhance cancer prognosis.

14 July 2021 in World Journal of Gastroenterology
Verified
Journal Article
Open access
PDPaulina Delgado-Gonzalez
Paulina Delgado-Gonzalez
CGCarlos A Gonzalez-Villarreal
Carlos A Gonzalez-Villarreal
JRJorge A Roacho-Perez
Jorge A Roacho-Perez
ARAdriana Guadalupe Quiroz Reyes
Adriana Guadalupe Quiroz Reyes
JIJose Francisco Islas
Jose Francisco Islas
EGElsa Garza-Treviño
Elsa Garza-Treviño
Inflammatory effect on the gastrointestinal system associated with COVID-19

16 August 2022 in Cancers
Verified
Journal Article
Open access
PDF file
JIJose Francisco Islas
Jose Francisco Islas
ARAdriana Guadalupe Quiroz Reyes
Adriana Guadalupe Quiroz Reyes
PDPaulina Delgado-Gonzalez
Paulina Delgado-Gonzalez
HFHector Franco-Villarreal
Hector Franco-Villarreal
JDJuan Luis Delgado
Juan Luis Delgado
CVCarlos Alberto González Villarreal
Carlos Alberto González Villarreal
Gastrointestinal adenocarcinomas are one of the world’s deadliest cancers. Cancer stem cells and the tissue microenvironment are highly regulated by cell and molecular mechanisms. Cancer stem cells are essential for maintenance and progression and are associated with resistance to conventional treatments. This article reviews the current knowledge of the role of the microenvironment during the primary establishment of gastrointestinal adenocarcinomas in the stomach, colon, and rectum and its relationship with cancer stem cells. We also describe novel developments in cancer therapeutics, such as targeted therapy, and discuss the advantages and disadvantages of different treatments for improving gastrointestinal cancer prognosis.

11 August 2021 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
EGElsa N. Garza‑Treviño
Elsa N. Garza‑Treviño
HMHerminia G. Martínez‑Rodríguez
Herminia G. Martínez‑Rodríguez
PDPaulina Delgado‑González
Paulina Delgado‑González
OSOrlando Solís‑Coronado
Orlando Solís‑Coronado
RORocio Ortíz‑Lopez
Rocio Ortíz‑Lopez
SSSalvador L. Said‑Fernández
Salvador L. Said‑Fernández
Colorectal cancer (CRC) is one of the main causes of mortality. Recent studies suggest that cancer stem cells (CSCs) can survive after chemotherapy and promote tumor invasiveness and aggression. According to a higher hierarchy complexity of CSC, different protocols for isolation, expansion, and characterization have been used; however, there are no available resistance biomarkers that allow predicting the clinical response of treatment 5‑fluorouracil (5FU) and oxaliplatin. Therefore, the primary aim of the present study was to analyze the expression of gene resistance on tumors and CSC‑derived isolates from patients CRC. In the present study, adenocarcinomas of the colon and rectum (CRAC) were classified based on an in vitro adenosine triphosphate‑based chemotherapy response assay, as sensitive and resistant and the percentage of CD24 and CD44 markers are evaluated by immunohistochemistry. To isolate resistant colon‑CSC, adenocarcinoma tissues resistant to 5FU and oxaliplatin were evaluated. Finally, all samples were sequenced using a custom assay with chemoresistance‑associated genes to find a candidate gene on resistance colon‑CSC. Results showed that 59% of the CRC tissue analyzed was resistant and had a higher percentage of CD44 and CD24 markers. An association was found in the expression of some genes between the tumor‑resistant tissue and CSC. Overall, isolates of the CSC population CD44+ resistant to 5FU and oxaliplatin demonstrated different expression profiles; however, the present study was able to identify overexpression of the KRT‑18 gene, in most of the isolates. In conclusion, the results of the present study showed overexpression of KRT‑18 in CD44+ cells is associated with chemoresistance to 5FU and oxaliplatin in CRAC.